Table 5.
Proportions of plasma EPA and DHA after treatment, stratified by ELOVL2 rs953413 genotype
| Treatment | n (GG/GA + AA)a | EPA | DHA | ||||
|---|---|---|---|---|---|---|---|
| GG | GA + AA | P* | GG | GA + AA | P* | ||
| Placebo | 21/45 | 1.00 (0.86,1.14) | 0.96 (0.87,1.06) | 0.934 | 2.22 (2.07,2.37) | 2.22 (2.12,2.32) | 0.544 |
| 0.45 g/day | 15/54 | 2.10 (1.70,2.51) | 1.77 (1.55,1.98) | 0.199 | 3.00 (2.75,3.25) | 2.85 (2.72,2.98) | 0.189 |
| 0.90 g/day | 23/52 | 2.55 (2.27,2.83) | 2.27 (2.09,2.46) | 0.050 | 3.35 (3.15,3.56) | 3.34 (3.21,3.48) | 0.671 |
| 1.80 g/day | 20/50 | 3.23 (2.75,3.72) | 4.19 (3.88,4.50) | 0.004 | 3.89 (3.65,4.13) | 4.21 (4.06,4.36) | 0.017 |
Data show mean (95 % CI) follow-up values for EPA and DHA as a percentage of total fatty acids, adjusted for baseline. Subjects received supplements of EPA and DHA (1.51:1) at the daily doses shown for 6 month
EPA eicosapentaenoic acid; DHA docosahexaenoic acid
* Significance of genotype association with proportions of fatty acids with respect to SNP genotype based on a dominant model was tested by multivariate ANOVA. Interaction between genotype andtreatment was a significant determinant of EPA (P < 0.0001) and DHA (P = 0.032). All P-values were adjusted for baseline values, BMI, age, gender and ethnicity
a n = number of subjects in genotype groups GG and GA + AA